Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $52,313.60 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 4,087 shares of the business’s stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $12.80, for a total value of $52,313.60. Following the completion of the transaction, the insider owned 76,751 shares in the company, valued at approximately $982,412.80. This trade represents a 5.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $12.94 on Friday. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56. The business’s 50-day simple moving average is $9.73 and its 200 day simple moving average is $10.64. The stock has a market cap of $994.83 million, a price-to-earnings ratio of -4.36 and a beta of 2.33.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Thursday, October 9th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.19). Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%.The business had revenue of $7.89 million during the quarter, compared to analyst estimates of $16.06 million. On average, equities research analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Analysts Set New Price Targets

NRIX has been the subject of several research analyst reports. Stifel Nicolaus set a $33.00 price objective on Nurix Therapeutics in a report on Friday, October 10th. HC Wainwright lowered their price objective on Nurix Therapeutics from $33.00 to $28.00 and set a “buy” rating for the company in a report on Monday, October 27th. Wells Fargo & Company lowered their price objective on Nurix Therapeutics from $22.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, October 23rd. Stephens reissued an “overweight” rating and issued a $30.00 price objective on shares of Nurix Therapeutics in a report on Thursday, July 10th. Finally, Oppenheimer lowered their price objective on Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating for the company in a report on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $26.73.

Hedge Funds Weigh In On Nurix Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Arizona State Retirement System grew its holdings in shares of Nurix Therapeutics by 8.7% during the first quarter. Arizona State Retirement System now owns 17,253 shares of the company’s stock valued at $205,000 after purchasing an additional 1,385 shares during the last quarter. Jump Financial LLC grew its holdings in shares of Nurix Therapeutics by 1.9% during the first quarter. Jump Financial LLC now owns 76,060 shares of the company’s stock valued at $904,000 after purchasing an additional 1,441 shares during the last quarter. Corebridge Financial Inc. grew its holdings in shares of Nurix Therapeutics by 5.6% during the first quarter. Corebridge Financial Inc. now owns 36,849 shares of the company’s stock valued at $438,000 after purchasing an additional 1,942 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Nurix Therapeutics by 13.9% during the second quarter. Teacher Retirement System of Texas now owns 18,404 shares of the company’s stock valued at $210,000 after purchasing an additional 2,248 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Nurix Therapeutics by 13.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,829 shares of the company’s stock valued at $224,000 after purchasing an additional 2,260 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.